Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Fsd Pharma Inc Subordinate Voting Share (HUGE.CN)

Fsd Pharma Inc Subordinate Voting Share (HUGE.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 46,591
  • Shares Outstanding, K 38,505
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,285 K
  • 60-Month Beta 0.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.78
Trade HUGE.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.79
  • Most Recent Earnings -0.15 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Drug Specialty & Generic

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.060 +10.38%
on 05/12/22
1.400 -16.43%
on 04/21/22
-0.180 (-13.33%)
since 04/20/22
3-Month
1.020 +14.71%
on 03/24/22
1.410 -17.02%
on 04/20/22
+0.120 (+11.43%)
since 02/18/22
52-Week
1.010 +15.84%
on 02/07/22
2.660 -56.02%
on 06/03/21
-0.880 (-42.93%)
since 05/20/21

Most Recent Stories

More News
InvestmentPitch Media Video Discusses FSD Pharma, a Life Sciences Holding Company, and the Closing of its Sale of Non-Core Assets for $16.4 million

VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a life sciences holding company...

HUGE : 0.9000 (-2.43%)
HUGE.CN : 1.170 (-3.31%)
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“ FSD Pharma ” or the “ Company ”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is...

HUGE : 0.9000 (-2.43%)
HUGE.CN : 1.170 (-3.31%)
FSD Pharma Announces Dismissal of Derivative Complaint

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“ FSD Pharma ” or the “ Company ”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced...

HUGE : 0.9000 (-2.43%)
HUGE.CN : 1.170 (-3.31%)
FSD Pharma Announces Engagement with Tekkfund Capital and Share Issuance to Crystal Research Associates

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“ FSD Pharma ” or the “ Company ”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced...

HUGE : 0.9000 (-2.43%)
HUGE.CN : 1.170 (-3.31%)
FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“ FSD Pharma ” or the “ Company ”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced...

HUGE : 0.9000 (-2.43%)
HUGE.CN : 1.170 (-3.31%)
GILD : 63.84 (+0.90%)
BMY : 76.19 (+0.30%)
PFE : 52.47 (+3.59%)
FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced...

HUGE : 0.9000 (-2.43%)
HUGE.CN : 1.170 (-3.31%)
FSD Pharma Issues Corporate Updates

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced...

HUGE : 0.9000 (-2.43%)
HUGE.CN : 1.170 (-3.31%)
FSD Pharma Announces Filing of Year-End 2021 Results

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“ FSD Pharma ” or the “ Company ”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced...

HUGE : 0.9000 (-2.43%)
HUGE.CN : 1.170 (-3.31%)
FSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLC

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced...

HUGE : 0.9000 (-2.43%)
HUGE.CN : 1.170 (-3.31%)
InvestmentPitch Media Video Discusses FSD Pharma’s, a Life Sciences Holding Company, Agreement to Sell Former Cannabis Processing Facility in Cobourg, Ontario for $16,500,000 – Video Available on Investmentpitch.com

VANCOUVER, British Columbia, Feb. 28, 2022 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9), a life sciences holding company...

HUGE : 0.9000 (-2.43%)
HUGE.CN : 1.170 (-3.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 1.220
2nd Resistance Point 1.210
1st Resistance Point 1.190
Last Price 1.170
1st Support Level 1.160
2nd Support Level 1.150
3rd Support Level 1.130

See More

52-Week High 2.660
Fibonacci 61.8% 2.030
Fibonacci 50% 1.835
Fibonacci 38.2% 1.640
Last Price 1.170
52-Week Low 1.010

See More

Business Summary

FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative and inflammatory disorders. The three licensed drug candidates are LUCID-MS, a new chemical entity targeting multiple sclerosis, LUCID-PSYCH, a psychoactive...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar